BPI 460372
Alternative Names: BPI-460372Latest Information Update: 22 Jun 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacokinetics and adverse events data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 08 Jun 2023 Phase-I clinical trials in Solid tumours in USA (PO) (Betta Pharmaceuticals pipeline, June 2023)